New Haven clinical-stage drug developer Trevi Therapeutics Inc. announced that David Hastings has been hired as its new chief financial officer, effective Jan. 6, 2026.
Hastings, 64, previously served as CFO of Arbutus Biopharma Corp. until March 2025, and before that held senior financial roles at Incyte Corp. and Unilife Corp.
Under the terms of his offer letter, disclosed in a U.S. Securities & Exchange Commission filing, Hastings will receive an annual base salary of $522,000, be eligible for an annual bonus of up to 40% of base salary, and be granted an option to purchase 375,000 common shares, vesting over four years.
Hastings replaces Lisa Delfini, who left the company in August.
Trevi is developing an experimental drug, Haduvio, to treat chronic cough in patients with idiopathic pulmonary fibrosis, other interstitial lung diseases and persistent chronic cough.
